Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm

  • Charlotte Pawlyn
  • Fredrik H Schjesvold
  • David A Cairns
  • L J Wei
  • Faith Davies
  • Omar Nadeem
  • Haifaa Abdulhaq
  • Maria-Victoria Mateos
  • Jacob Laubach
  • Katja Weisel
  • Heinz Ludwig
  • S Vincent Rajkumar
  • Pieter Sonneveld
  • Graham Jackson
  • Gareth Morgan (Geteilte/r Letztautor/in)
  • Paul G Richardson (Geteilte/r Letztautor/in)

Beteiligte Einrichtungen

Abstract

Measurement of overall survival (OS) remains the gold standard for interpreting the impact of new therapies for multiple myeloma in phase 3 trials. However, as outcomes have improved, it is increasingly challenging to use OS as the primary endpoint if timely approval of novel agents is to be ensured to enable maximum benefit for patients. Surrogate endpoints of OS, such as progression-free survival (PFS) and response to treatment, have contributed to approval decisions by the Food and Drug Administration (FDA) and European Medicines Agency as endpoints demonstrating clinical benefit, and the FDA has recently supported the use of minimal residual disease (MRD) as an accelerated approval endpoint in multiple myeloma. This review aims to address situations in which the use of PFS as a surrogate endpoint warrants careful interpretation especially for specific subgroups of patients and considers ways to ensure that studies can be designed to account for possible discordance between PFS and OS. The utility of subgroup analyses, including the potential for those not pre-specified, to identify target populations for new agents is also discussed.

Bibliografische Daten

OriginalspracheEnglisch
ISSN2044-5385
DOIs
StatusVeröffentlicht - 12.08.2024

Anmerkungen des Dekanats

© 2024. The Author(s).

PubMed 39134544